Overexpression of vimentin: Role in the invasive phenotype in an androgen-independent model of prostate cancer

Cancer Research

Volumn 63, Issue 9, 2003, Pages 2306-2311

  Singh, Sadmeet ^a   Sadacharan, Skanda ^a   Su, Scott ^a   Belldegrun, Arie ^b   Persad, Sujata ^a   Singh, Gurmit ^a  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL INVASION; CONTROLLED STUDY; GENE CONSTRUCT; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; NUCLEIC ACID PROBE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION;

ANDROGENS; CELL MOVEMENT; DNA, ANTISENSE; DNA, COMPLEMENTARY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KERATINS; MALE; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROSTATIC NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION; VIMENTIN;

EID: 0037699018     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Turkes, A. O., and Griffiths, K. Endocrine treatment of prostate cancer. Prog. Med. Chem., 26: 299-321, 1989.
2. Tso, C. L., McBride, W. H., Sun, J., Patel, B., Tsui, K. H., Paik, S. H., Gitlitz, B., Caliliw, R., Ophoven, A., Wu, L., deKernion, J., and Belldegrun, A. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J., 6: 220-233, 2000.
3. Hendrix, M. J., Seftor, E. A., Seftor, R. E., and Trevor, K. T. Experimental coexpression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. Am. J. Pathol., 150: 483-495, 1997.
4. Singh, D., Febbo, P. G., Ross, K., Jackson, D. G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A. A., D'Amico, A. V., Richie, J. P., Lander, E. S., Loda, M., Kantoff, P. W., Golub, T. R., and Sellers, W. R. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell, 1: 203-209, 2002.
5. Welsh, J. B., Sapinoso, L. M., Su, A. I., Kern, S. G., Wang-Rodriguez, J., Moskaluk, C. A., Frierson, H. F., Jr., and Hampton, G. M. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res., 61: 5974-5978, 2001.
6. Mousses, S., Bubendorf, L., Wagner, U., Hostetter, G., Kononen, J., Cornelison, R., Goldberger, N., Elkahloun, A. G., Willi, N., Koivisto, P., Ferhle, W., Raffeld, M., Sauter, G., and Kallioniemi, O. P. Clinical validation of candidate genes associated with prostate cancer progression in the CWR22 model system using tissue microarrays. Cancer Res., 62: 1256-1260, 2002.
7. Osborn, M., and Weber, K. Intermediate filaments: cell-type-specific markers in differentiation and pathology. Cell, 31: 303-306, 1982.
8. Steinert, P. M., Steven, A. C., and Roop, D. R. The molecular biology of intermediate filaments. Cell, 42: 411-420, 1985.
9. Huszar, M., Halkin, H., Herczeg, E., Bubis, J., and Geiger, B. Use of antibodies to intermediate filaments in the diagnosis of metastatic amelanotic malignant melanoma. Hum. Pathol., 14: 1006-1008, 1983.
10. Moll, R., Franke, W. W., Schiller, D. L., Geiger, B., and Krepler, R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell, 31: 11-24, 1982.
11. Leong, A. S., Gilham, P., and Milios, J. Cytokeratin and vimentin intermediate filament proteins in benign and neoplastic prostatic epithelium. Histopathology, 13: 435-442, 1988.
12. Ramaekers, F. C., Haag, D., Kant, A., Moesker, O., Jap, P. H., and Vooijs, G. P. Coexpression of keratin and vimentin type intermediate filaments in human metastatic carcinoma cells. Proc. Natl. Acad. Sci. USA, 80: 2618-2622, 1983.
13. Sommers, C. L., Walker-Jones, D., Heckford, S. E., Worland, P., Valverius, E., Clark, R., McCormick, F., Stampfer, M., Abularach, S., and Gelmann, E. P. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res., 49: 4258-4263, 1989.
14. Azumi, N., and Battifora, H. The distribution of vimentin and keratin in epithelial and nonepithelial neoplasms. A comprehensive immunohistochemical study on form. Am. J. Clin. Pathol., 88: 286-296, 1987.
15. Hendrix, M. J., Seftor, E. A., Chu, Y. W., Seftor, R. E., Nagle, R. B., McDaniel, K. M., Leong, S. P., Yohem, K. H., Leibovitz, A. M., Meyskens, F. L., Jr., et al. Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential. J. Natl. Cancer Inst. (Bethesda), 84: 165-174, 1992.
16. Thomas, P. A., Kirschmann, D. A., Cerhan, J. R., Folberg, R., Seftor, E. A., Sellers, T. A., and Hendrix, M. J. Association between keratin and vimentin expression, malignant phenotype, and survival in postmenopausal breast cancer patients. Cancer Res., 5: 2698-2703, 1999.
17. Hay, E. D. An overview of epithelio-mesenchymal transformation. Acta Anat., 154: 8-20, 1995.
18. Birchmeier, C., Birchmeier, W., and Brand-Saberi, B. Epithelial-mesenchymal transitions in cancer progression. Acta Anat., 156: 217-226, 1996.
19. Gilles, C., Polette, M., Birembaut, P., Brunner, N., and Thompson, E. W. Expression of c-ets-1 mRNA is associated with an invasive, EMT-derived phenotype in breast carcinoma cell lines. Clin. Exp. Metastasis, 15: 519-526, 1997.
20. Lochter, A., Galosy, S., Muschler, J., Freedman, N., Werb, Z., and Bissell, M. J. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J. Cell Biol., 139: 1861-1872, 1997.
21. Nagle, R. B., Ahmann, F. R., McDaniel, K. M., Paquin, M. L., Clark, V. A., and Celniker, A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res., 47: 281-286, 1987.
22. Mitchell, S., Abel, P., Ware, M., Stamp, G., and Lalani, E. Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int., 85: 932-944, 2000.
23. Heatley, M., Maxwell, P., Whiteside, C., and Toner, P. Vimentin and cytokeratin expression in nodular hyperplasia and carcinoma of the prostate. J. Clin. Pathol., 48: 1031-1034, 1995.
24. Lang, S. H., Hyde, C., Reid, I. N., Hitchcock, I. S., Hart, C. A., Bryden, G. A. A., Villette, J. M., Stower, M. J., and Maitland, M. J. Enhanced expression of vimentin in motile prostate cancer cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate, 52: 253-263, 2002.
25. Lim, D. J., Liu, X. L., Sutkowski, D. M., Braun, E. J., Lee, C., and Kozlowski, J. M. Growth of an androgen-sensitive human prostate cancer cell line, LNCaP, in nude mice. Prostate, 22: 109-118, 1993.
26. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C., Trapman, J., Brinkmann, A. O., and Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 173: 534-540, 1990.
27. Thompson, E. W., Paik, S., Brunner, N., Sommers, C. L., Zugmaier, G., Clarke, R., Shima, T. B., Torri, J., Donahue, S., and Lippman, M. E., et al. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J. Cell. Physiol., 150: 534-544, 1992.
28. Sommers, C. L., Heckford, S. E., Skerker, J. M., Worland, P., Torri, J. A., Thompson, E. W., Byers, S. W., and Gelmann, E. P. Loss of epithelial markers and acquisition of vimentin expression in adriam. Cancer Res., 52: 5190-5197, 1992.
29. Bussemakers, M. J., Verhaegh, G. W., van Bokhoven, A., Debruyne, F. M., and Schalken, J. A. Differential expression of vimentin in rat prostatic tumors. Biochem. Biophys. Res. Commun., 182: 1254-1259, 1992.
30. Kryszke, M. H., and Vicart, P. Regulation of the expression of the human vimentin gene: application to cellular immortalization. Pathol. Biol. (Paris), 46: 39-45, 1998.
31. Ginsberg, M. H., Du, X., and Plow, E. F. Inside-out integrin signalling. Curr. Opin. Cell Biol., 3: 841-848, 1992.
32. Juliano, R. L., and Haskill, S. Signal transduction from the extracellular matrix. J. Cell Biol., 120: 577-585, 1993.
33. Maniotis, A. J., Chen, C. S., and Ingber, D. E. Control of cell and nuclear shape by mechanical stresses transmitted from integrins to the nucleus over direct cytoskeletal interconnections. Proc. Natl. Acad. Sci. USA, 94: 849-854, 1997.
34. Miyamato, S., Teramoto, H., Coso, O. A., Gutkind, J. S., Burbelo, P. D., Akiyama, S. K., and Yamada, K. M. Integrin function: molecular hierarchies of cytoskeletal and signaling molecules. J. Cell Biol., 131: 791-805, 1995.
35. Cress, A. E., and Dalton, W. S. Multiple drug resistance and intermediate filaments. Cancer Metastisis Rev., 15: 499-506, 1996.